SHARE BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Schedule of share-based compensation awards granted for options and RSUs during the period

In the years ended December 31, 2021 and 2020, the Company granted options as follows:

	Year ended December 31, 2021
	Award amount	Exercise price range	Vesting period	Expiration
Employees and Directors:
Options	1,686,405	$1.68- $11.08	1 year -4 years	10 years
RSU	970,813	—	2 years -4 years	—

	Year ended December 31, 2020
	Award amount	Exercise price range	Vesting period	Expiration
Employees and Directors:
Options	1,327,214	$5.84- $12.52	1 year -4 years	10 years
RSU	654,427	—	1 year -4 years	—

Summary of underlying data used for computing the fair value of the options

The underlying data used for computing the fair value of the options are as follows:

	Year ended December 31
	2021		2020
Fair value of stock option	$1.02-$6.75		$3.47-$7.68
Dividend yield	0	%	0	%
Expected volatility	68.38%-69.38%		60.44%-69.83%
Risk-free interest rate	0.50%-1.29%		0.31%-1.26%
Expected term	6 years		6 years

Summary of the number of options outstanding

The following table summarizes the number of options outstanding for the year ended December 31, 2021, and related information:

	Number of options	Weighted Average Exercise Price
Outstanding at December 31, 2020	4,274,649	$	13.36
Granted	1,686,405	5.29
Exercised	(70,827)	7.18
Forfeited	(435,569)	8.25
Expired	(1,410,706)	17.53
Outstanding at December 31, 2021	4,043,952	$	9.20
Exercisable at December 31, 2021	1,971,922	$	12.39

Summary of the number of RSUs outstanding

The following table summarizes the number of RSUs outstanding for the year ended December 31, 2021:

	Number of RSUs
Outstanding at December 31, 2020	719,443
Awarded	970,813
Vested	(293,034)
Forfeited	(134,822)
Outstanding at December 31, 2021	1,262,400

Summary of share-based compensation expenses

The following table illustrates the effect of share-based compensation on the statements of operations:

	Year ended December 31
	2021		2020
Research and development expenses	1,714		4,746
Selling, general and administrative	6,366		13,354
	$	8,080	$	18,100